Characteristics and Glycemic Outcomes of T2D Patients (Pts) Titrated to 60 U/day with Insulin Glargine/Lixisenatide Fixed-Ratio Combination (iGlarLixi) vs. Insulin in the LixiLan-L Trial

被引：0
|
作者：
Blonde, Lawrence
Bailey, Timothy S.
Chao, Jason
Dex, Terry
Frias, Juan P.
Meneghini, Luigi F.
Roberts, Michelle
Aroda, Vanita R.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1107-P
引用
收藏
页码：A294 / A294
页数：1
相关论文
共 50 条
  • [21] More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L
    Frias, Juan
    Domingo, Manuel Puig
    Meneghini, Luigi
    Napoli, Raffaele
    Liu, Minzhi
    Rak, Erika Soltes
    Aroda, Vanita R.
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2314 - 2318
  • [22] Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
    Wysham, Carol
    Bonadonna, Riccardo C.
    Aroda, Vanita R.
    Puig Domingo, Manuel
    Kapitza, Christoph
    Stager, William
    Yu, Christine
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1408 - 1415
  • [23] Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes
    Kis, Janos Tibor
    Nagy, Gabor
    Kovacs, Gabor
    DIABETES THERAPY, 2021, 12 (09) : 2517 - 2529
  • [24] Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes
    János Tibor Kis
    Gábor Nagy
    Gábor Kovacs
    Diabetes Therapy, 2021, 12 : 2517 - 2529
  • [25] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial (vol 39, pg 1972, 2016)
    Aroda, Vanita R.
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Gonzalez-Galvez, Guillermo
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    DIABETES CARE, 2017, 40 (06) : 809 - 809
  • [26] Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials
    Davidson, J. A.
    Desouza, C.
    Fonseca, V.
    Frias, J. P.
    Van Gaal, L.
    Giorgino, F.
    Chao, J.
    Dex, T. A.
    Roberts, M.
    Saremi, A.
    Leiter, L. A.
    DIABETIC MEDICINE, 2020, 37 (02) : 256 - 266
  • [27] Efficacy and Safety of LixiLan vs. Insulin Glargine According to Baseline Characteristics in Patients with Type 2 Diabetes from the LixiLan-L Trial
    Wysham, Carol
    Bonadonna, Riccardo C.
    Aroda, Vanita
    Domingo, Manuel Puig
    Kapitza, Christoph
    Stager, William
    Yu, Christine
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard
    DIABETES, 2016, 65 : A265 - A265
  • [28] Impact of Lixisenatide (LIXI) Dose Range on Clinical Outcomes with Fixed-Ratio Combination (FRC) iGlarLixi in Patients With T2D
    Frias, Juan
    Hurst, William
    Newton, John
    Lorenz, Martin
    Roberts, Michelle
    Dex, Terry
    Schmider, Wolfgang
    Skolnik, Neil
    DIABETES, 2017, 66 : A291 - A292
  • [29] Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
    Rosenstock, Julio
    Aronson, Ronnie
    Grunberger, George
    Hanefeld, Markolf
    Piatti, PierMarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Davies, Melanie
    DIABETES CARE, 2016, 39 (11) : 2026 - 2035
  • [30] Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial
    Kaneto, Hideaki
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Watanabe, Daisuke
    Niemoeller, Elisabeth
    DIABETES OBESITY & METABOLISM, 2020, 22 : 3 - 13
12345